Crescent Biopharma, Inc. Common Stock (CBIO) Stock
Fundamentals
Latest news
About Crescent Biopharma, Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Joshua T. Brumm | CEO & Director | 1978 |
| Dr. Jonathan McNeill M.D. | President & COO | 1985 |
| Dr. Ellie Im M.D. | Chief Medical Officer | 1978 |
| Mr. Richard William Scalzo M.B.A. | Chief Financial Officer | 1986 |
| Mr. Ryan Lynch | Senior VP of Finance, Treasurer & Chief Accounting Officer | 1984 |
| Dr. Wenjie Cheng Ph.D. | Senior Vice President of Technical Operations | — |
| Dr. Jan Pinkas Ph.D. | Chief Scientific Officer | 1969 |
| Ms. Barbara Bispham Hale J.D. | General Counsel & Corporate Secretary | 1987 |
| Ms. Amy Reilly | Chief Communications Officer | 1974 |
| Mr. Christopher Doughty | Chief Business Officer | 1988 |



